Recently, it has been shown that depleting insulin-like growth factor binding protein 2 (IGFBP2) can lead to the sensitisation of STAT3-low expressing cells to STAT3 inhibitors, suggesting that targeting both the STAT3 and IGF-1R/IGFBP2 signalling axis is a promising therapeutic strategy for GBM [72]. This evidence concerns the gene IGFBP2 and glioblastoma.